Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
paclitaxel + cisplatin + fluorouracil + leucovorin
- Development stage
- Unknown
- Lead developer
- National Taiwan University Hospital
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
Weekly TP-HDFL is a combination chemotherapy regimen developed by researchers at National Taiwan University Hospital for the treatment of advanced transitional cell carcinoma (TCC). The regimen consists of weekly administrations of paclitaxel, cisplatin, and a 24-hour infusion of high-dose 5-fluorouracil (5-FU) modulated by leucovorin. Paclitaxel acts as a microtubule stabilizer, cisplatin is a platinum-based DNA alkylating agent, and 5-fluorouracil is an antimetabolite that inhibits thymidylate synthase. Leucovorin is included to enhance the binding of 5-FU to its target enzyme. This specific combination aims to provide a high dose-intensity while maintaining a manageable toxicity profile for patients with advanced urothelial or transitional cell cancers.
- Other names
- Weekly Paclitaxel, Cisplatin, and 24-Hour Infusion of High-Dose 5-Fluorouracil and Leucovorin
02
Targets
TUBB (Tubulin (alpha and beta subunits))TS (Thymidylate synthase)DNA
Beyond the preview
Go deeper on paclitaxel + cisplatin + fluorouracil + leucovorin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on paclitaxel + cisplatin + fluorouracil + leucovorin.